0000899243-15-010542.txt : 20151231
0000899243-15-010542.hdr.sgml : 20151231
20151231160521
ACCESSION NUMBER: 0000899243-15-010542
CONFORMED SUBMISSION TYPE: 4
PUBLIC DOCUMENT COUNT: 1
CONFORMED PERIOD OF REPORT: 20151230
FILED AS OF DATE: 20151231
DATE AS OF CHANGE: 20151231
ISSUER:
COMPANY DATA:
COMPANY CONFORMED NAME: Carbylan Therapeutics, Inc.
CENTRAL INDEX KEY: 0001348911
STANDARD INDUSTRIAL CLASSIFICATION: PHARMACEUTICAL PREPARATIONS [2834]
IRS NUMBER: 200915291
FISCAL YEAR END: 1231
BUSINESS ADDRESS:
STREET 1: 3181 PORTER DRIVE
CITY: PALO ALTO
STATE: CA
ZIP: 94304
BUSINESS PHONE: 650-855-6777
MAIL ADDRESS:
STREET 1: 3181 PORTER DRIVE
CITY: PALO ALTO
STATE: CA
ZIP: 94304
FORMER COMPANY:
FORMER CONFORMED NAME: Carbylan Biosurgery, Inc
DATE OF NAME CHANGE: 20130102
FORMER COMPANY:
FORMER CONFORMED NAME: Carbylan Biosurgery Inc
DATE OF NAME CHANGE: 20060105
REPORTING-OWNER:
OWNER DATA:
COMPANY CONFORMED NAME: Renzi David
CENTRAL INDEX KEY: 0001631294
FILING VALUES:
FORM TYPE: 4
SEC ACT: 1934 Act
SEC FILE NUMBER: 001-36830
FILM NUMBER: 151315956
MAIL ADDRESS:
STREET 1: C/O CARBYLAN THERAPEUTICS, INC.
STREET 2: 3181 PORTER DRIVE
CITY: PALO ALTO
STATE: CA
ZIP: 94304
4
1
doc4.xml
FORM 4 SUBMISSION
X0306
4
2015-12-30
0
0001348911
Carbylan Therapeutics, Inc.
CBYL
0001631294
Renzi David
C/O CARBYLAN THERAPEUTICS, INC.
3181 PORTER DRIVE
PALO ALTO
CA
94304
1
1
0
0
President & CEO
Common Stock
2015-12-30
4
M
0
10000
0.56
A
10000
D
Common Stock
2015-12-30
4
S
0
10000
3.70
D
0
D
Stock Option (Right to Buy)
0.56
2015-12-30
4
M
0
10000
0.00
D
2023-06-06
Common Stock
10000
515825
D
The sales reported on this Form 4 were effected pursuant to a trading plan adopted pursuant to Rule 10b5-1 under the Securities Exchange Act of 1934, as amended.
Represents the weighted-average price at which shares were sold within a range between $3.65 and $3.725, inclusive. The reporting person hereby undertakes to provide, upon request, to the SEC staff, the issuer or a security holder of the issuer full information regarding the number of shares and prices at which the transaction was effected.
The option for 525,825 shares of common stock was granted on 6/6/2013. 1/4 of the option grant was fully vested and exercisable on 6/6/2014, and 1/48 of the option grant vests and becomes exercisable each month thereafter.
/s/ David J. Saul, Attorney-in-fact
2015-12-31